Autoimmune diseaseImmunology & inflammationGastroenterology PopPKExposure-response

Vedolizumab clearance and exposure

Reference paper ↗

A two-compartment population PK model representing vedolizumab central and peripheral disposition, prior anti-TNF effects on clearance, concentration, and cumulative exposure.

Therapeutic
Vedolizumab
Modality
Monoclonal antibody
Target
Integrin α4β7
Disease
Inflammatory bowel disease
Model type
PopPK, Exposure-response

Complete model workspace

Checking workspace access…

Parameters
6
States
3
Equations
3
Derived outputs
7

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

0-2-6w + 10w + every 4 weeks, prior anti-TNF no

How do regimen and prior anti-TNF therapy change vedolizumab clearance and exposure? Explore this intervention regimen through Central vedolizumab concentration, Cumulative vedolizumab exposure, Effective clearance.

Starting result

This result reflects the starting settings. Run your changes to update it.

Result preview could not load

The generated result could not be loaded. The inputs remain available below.

Starting configuration

Time: 0–630 day; step 1

InputDefaultAvailable range
Systemic clearance0.159 L/day0.0795–0.2385 L/day
Central distribution volume3.19 L1.595–4.785 L
Intercompartmental clearance0.12 L/day0.06–0.18 L/day
Peripheral distribution volume1.66 L0.83–2.49 L
Anti-TNF effect0.264 dimensionless0.132–0.396 dimensionless

Expected readouts

Central vedolizumab concentration · Cumulative vedolizumab exposure · Effective clearance

Adjustable model parameters

This public explorer exposes 5 curated parameters. Sign in to edit all 6 declared model parameters.

More key parameters (1)

How the model represents the biology

A two-compartment population PK model representing vedolizumab central and peripheral disposition, prior anti-TNF effects on clearance, concentration, and cumulative exposure.

How does prior anti-TNF status alter vedolizumab clearance and exposure?Intravenous vedolizumab enters a central pool, exchanges with a peripheral pool, undergoes systemic clearance, and accumulates central exposure. Prior anti-TNF status empirically modifies clearance.BIOLOGY OVERVIEWHow does prior anti-TNF status alter vedolizumab clearance and exposure?IV vedolizumabInfusion to central amountCentral exposureVedolizumab concentrationPeripheral poolReversible distributionSystemic clearanceEffective concentration lossPrior anti-TNF statusBinary clearance covariateCumulative exposureCentral concentration integralPRIMARY READOUTSCentral vedolizumab concentrationCentral vedolizumab concen…Cumulative exposureCumulative exposureEffective clearanceEffective clearance

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: α4β7 binding, gut lymphocyte trafficking, inflammation, remission probability, and exposure-response endpoints are not represented; prior anti-TNF is an empirical PK covariate.

Modeled relationships (5)
  • IV vedolizumab → Central exposure: IV input (flow)
  • Central exposure ↔ Peripheral pool: distribution (reversible exchange)
  • Central exposure → Systemic clearance: systemic CL (loss)
  • Prior anti-TNF status → Systemic clearance: modifies CL (modulation)
  • Central exposure → Cumulative exposure: integrates C (production)

Modeled relationships: IV vedolizumab to Central exposure: IV input (flow); Central exposure reversibly exchanges with Peripheral pool: distribution (reversible exchange); Central exposure to Systemic clearance: systemic CL (loss); Prior anti-TNF status to Systemic clearance: modifies CL (modulation); Central exposure to Cumulative exposure: integrates C (production).

Primary readouts: Central vedolizumab concentration; Cumulative exposure; Effective clearance.

Found a scientific issue? Email helpdesk@unibiointelligence.com with model ID markovic_2024_vedolizumab_clearance_remission_poppk.

Research use only — not for patient-specific prediction or dosing advice.

Ubi Biologics